ISPOR - Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries

Full Text

Health Loss Due To Market Access Delays And Reimbursement Restrictions In First-Line EGFR-Positive Non-Small Cell Lung Cancer In The EU5 Countries

Abstract

Authors

K van Nimwegen K Nientker S Boukouvalas

Back to Volume 20, Issue 9

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now